FDA Nanotechnology Oversight Limited By Budget Constraints – Report

FDA's budget constraints and gaps in its legal authority hinder its ability to understand and manage nanotechnology's potential risks, according to Michael Taylor, professor at the University of Maryland School of Medicine and former FDA deputy commissioner for policy